Zhejiang Jolly Pharmaceutical 佐力药业
29 significant filings since 29 May 2026: 19 on share issue, 8 on equity incentive and 1 on dividend, and 1 other kind. The latest, on 15 Sep 2026: 2026年半年度权益分派实施公告.
自 29 May 2026 起有 29 份重大公告：share issue 19 份、equity incentive 8 份、dividend 1 份，另有 1 类。最新一份（15 Sep 2026）：2026年半年度权益分派实施公告。
As of 25 Sep 2026 截至2026年9月25日
Zhejiang Jolly Pharmaceutical 佐力药业 is a traditional Chinese medicine company listed on the Shenzhen Stock Exchange since 22 Feb 2011. The company reported revenue of RMB3.04bn in 2025, up 18.0% from RMB2.58bn in 2024, with attributable net profit rising to RMB631.9m from RMB507.8m. Profitability metrics improved, including a net margin of 21.1% and ROE of 21.4%. At 30 Jun 2026, liabilities to assets stood at 34.9%, with a current ratio of 1.53. Operating cash flow per share was RMB0.59 in 2025, below net profit per share of RMB0.92. In the six months to 30 Jun 2026, revenue rose 10.3% to RMB1.76bn, but attributable net profit grew only 0.4% to RMB374.9m. One litigation-related filing was made in the past 12 months. Risk warnings are not shown.
佐力药业是一家中药企业，2011年2月22日在深圳证券交易所上市。2025年营业收入为30.41亿元，较2024年的25.78亿元同比上升18.0%；归属于母公司股东的净利润增至6.32亿元，2024年为5.08亿元。盈利能力改善，净利率达21.1%，净资产收益率为21.4%。截至2026年6月30日，资产负债率为34.9%，流动比率为1.53。2025年每股经营现金流为0.59元，低于基本每股收益0.92元。2026年上半年营业收入达17.64亿元，同比增10.3%，归母净利润为3.75亿元，同比仅增0.4%。近12个月有一份涉诉进展公告。风险警示未列示。
- Change in attributable net profit for the full year 2026
2026全年归母净利润变动情况 - Operating cash flow to net profit ratio in 2026
2026年经营现金流与净利润之比 - Receivable days and inventory days at 31 Dec 2026
2026年12月31日的应收账款周转天数与存货周转天数 - New litigation filings involving the company or its subsidiaries
公司或其子公司涉及新的诉讼公告 - Revenue growth in the second half of 2026 compared to the first half
2026年下半年收入增长与上半年比较 - Pledge or freeze status of the shares held by 俞有强
俞有强所持股份的质押或冻结状态
- Company: Zhejiang Jolly Pharmaceutical 佐力药业, Shenzhen Stock Exchange 300181; industry Traditional Chinese Medicine; listed 22 Feb 2011.
公司：佐力药业，深圳证券交易所 300181；行业：中药；上市日期：2011年2月22日。 - Close on 24 Sep 2026 RMB12.95; close on 24 Sep 2025 RMB18.09, RMB17.19 in today's terms; one-year change, adjusted for distributions and share changes -24.7%.
2026年9月24日收盘价12.95元；2025年9月24日收盘价18.09元（前复权17.19元）；一年涨跌幅（复权）-24.7%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB12.50 to RMB18.17.
52周区间（前复权）12.50元至18.17元。 - Market capitalisation RMB9.08bn; P/E TTM 14.3; price to book 2.73x.
总市值90.83亿元；市盈率（TTM）14.3；市净率2.73倍。 - Revenue 2025 RMB3.04bn; 2024 RMB2.58bn; change +18.0%.
营业收入2025年30.41亿元；2024年25.78亿元；同比+18.0%。 - Attributable net profit 2025 RMB631.9m; 2024 RMB507.8m; change +24.5%.
归属于母公司股东的净利润2025年6.32亿元；2024年5.08亿元；同比+24.5%。 - Net profit excluding non-recurring items, 2025 change +21.6%.
2025年扣除非经常性损益后的净利润同比+21.6%。 - Basic EPS 2025 RMB0.92; 2024 RMB0.73.
基本每股收益2025年0.92元；2024年0.73元。 - Operating cash flow per share 2025 RMB0.59; 2024 RMB0.42; operating cash flow to net profit 0.64x.
每股经营现金流2025年0.59元；2024年0.42元；经营现金流与净利润之比0.64倍。 - 2025 gross margin 61.6%; net margin 21.1%; ROE 21.4%.
2025年毛利率61.6%；净利率21.1%；净资产收益率21.4%。 - At 30 Jun 2026: liabilities to assets 34.9%; current ratio 1.53; quick ratio 1.18; receivable days 90; inventory days 150.
截至2026年6月30日：资产负债率34.9%；流动比率1.53；速动比率1.18；应收账款周转天数90；存货周转天数150。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB1.76bn, change +10.3%; attributable net profit RMB374.9m, change +0.4%; operating cash flow per share RMB0.33.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入17.64亿元，同比+10.3%；归母净利润3.75亿元，同比+0.4%；每股经营现金流0.33元。 - In the 12 months to 25 Sep 2026: 1 distinct filing classed critical, high or as a lift; by class: 1 filing classed Litigation. One filing can fall in more than one class, and several filings can concern one matter, such as the notice and the result of one auction.
截至2026年9月25日的近12个月：被归为重大、较高级别或解除类的公告共1份；按类别：归为诉讼仲裁的公告1份。同一公告可属多个类别，同一事项亦可有多份公告，例如同一拍卖的提示公告与结果公告。 - 26 Feb 2026, Litigation (high): filing titled 《关于控股子公司涉诉的进展公告》.
2026年2月26日，诉讼仲裁：公告《关于控股子公司涉诉的进展公告》。 - Ownership: actual controller 俞有强; largest holder at 30 Jun 2026: 俞有强, 18.52%.
股权：实际控制人：俞有强；2026年6月30日第一大股东：俞有强，持股18.52%。 - Latest distribution: ex-date 23 Sep 2026, cash RMB0.35 per share.
最近一次分配：除权除息日2026年9月23日，每股现金0.35元。 - Aurelian Grade C, score 62.2 of 100, graded within a peer group of 66 companies in its industry; no rank among peers is given.
金源评级C，得分62.2（满分100），于行业同业66家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。